Uveitis is inflammation of the middle layer of the eye, called the uvea, which can cause pain, redness, and vision problems. When caught early and treated properly, many people can preserve their vision and manage the condition effectively.

Understanding Treatment Goals for Eye Inflammation

When someone develops uveitis, the main focus of treatment is to reduce inflammation inside the eye as quickly as possible. This helps control symptoms like pain and redness, prevents complications, and most importantly, protects vision from permanent damage. Because the space inside the eyeball is limited, even small amounts of swelling can change the eye’s shape and disrupt how well a person can see.^[1]

The approach to treating uveitis depends on several factors, including which part of the eye is affected, whether one or both eyes are involved, what caused the inflammation, and how severe the condition is. Anterior uveitis, which affects the front of the eye (the iris and ciliary body), is the most common type and usually responds well to treatment. Intermediate uveitis affects the middle part of the eye, while posterior uveitis affects the back of the eye (the retina and choroid). When all parts are affected, it’s called panuveitis.^[2]

Treatment needs to be tailored to each person because uveitis can appear suddenly and improve quickly, or it can become a chronic condition that requires long-term management. Between 50 and 70 percent of cases have no identifiable cause, which doctors call idiopathic uveitis. Even when a specific cause cannot be found, treatment can still be very successful in controlling inflammation and preventing vision loss.^[1]

Medical societies have established standard treatments that have been proven effective through years of research and clinical practice. At the same time, researchers continue to explore new therapies through clinical trials, searching for treatments that may work better, have fewer side effects, or help people who don’t respond to existing options. These investigational approaches represent hope for improved outcomes in the future.

Standard Approaches to Managing Uveitis

The cornerstone of uveitis treatment has traditionally been medications called corticosteroids, commonly known as steroids. These powerful anti-inflammatory drugs work by reducing the immune system’s activity in the eye, which decreases swelling, pain, and other symptoms. Steroids can ease symptoms and help prevent vision loss by controlling inflammation before it causes permanent damage to delicate eye structures.^[3]

For anterior uveitis, which affects the front of the eye, doctors typically prescribe steroid eye drops. These drops are applied directly to the affected eye several times a day. The advantage of eye drops is that they deliver medication right where it’s needed, with less impact on the rest of the body. Patients may also receive dilating eye drops, which help relieve pain by relaxing the muscles in the eye and preventing complications like irregular pupil shape.^[1]

When uveitis affects the middle or back of the eye, eye drops often cannot reach the inflamed areas effectively. In these cases, doctors may use steroids in other forms. Oral corticosteroids (pills) can be prescribed to treat inflammation throughout the body, including deep inside the eye. Some patients receive steroid injections directly into or around the eye, allowing higher concentrations of medication to reach the affected tissues.^[3]

To address concerns about side effects from long-term steroid use, medical device manufacturers have developed steroid implants that can be placed inside the eye. The dexamethasone intravitreal implant (Ozurdex) and the fluocinolone acetonide implant (Yutiq) are examples of these newer-generation devices. They release small amounts of steroid medication slowly over time, providing sustained treatment while potentially reducing the need for frequent injections or pills. The fluocinolone acetonide implant can continue releasing medication for up to three years.^[11][15]

When steroids alone are not sufficient, or when the side effects become problematic, doctors often add immunosuppressive medications to the treatment plan. These drugs work by calming down the immune system in different ways than steroids do. Antimetabolites like methotrexate and mycophenolate mofetil are commonly used as first-line immunosuppressants because they are relatively affordable, have a favorable safety profile, and are generally well tolerated by patients.^[11]

Research comparing methotrexate and mycophenolate mofetil found that both drugs work similarly well in helping patients reduce their steroid use while maintaining control of inflammation. They also showed similar benefits in improving vision and resolving swelling in the macula, the central part of the retina responsible for sharp vision. However, methotrexate was more likely to cause liver function test abnormalities, while mycophenolate mofetil did not increase the risk of certain white blood cell problems during the first year of treatment.^[11]

The duration of treatment varies considerably depending on the type and cause of uveitis. Acute anterior uveitis may resolve within weeks with aggressive treatment, while chronic forms of uveitis may require months or even years of ongoing therapy. Patients need regular follow-up appointments so their doctor can monitor the inflammation, adjust medications as needed, and watch for complications or side effects.

Innovative Therapies Being Studied in Clinical Trials

Clinical research continues to explore new treatment options for uveitis, particularly for people who don’t respond well to standard therapies or who experience intolerable side effects. These studies are organized into phases that help researchers understand how safe and effective new treatments are.

Phase I trials focus primarily on safety, testing new treatments in a small number of people to identify potential side effects and determine appropriate doses. Phase II trials expand to larger groups to evaluate whether the treatment actually works to reduce inflammation and improve symptoms. Phase III trials involve even more patients and compare the new treatment directly against current standard treatments to see if it offers advantages.^[11]

One of the most significant advances in recent years has been the use of biologic medications, which are treatments derived from living cells that target very specific parts of the immune system. These drugs are often used when conventional immunosuppressants fail to control inflammation or when patients cannot tolerate them. Biologics work by blocking specific proteins or cells that drive inflammation, offering a more targeted approach than traditional medications.

Adalimumab is a biologic medication that has been extensively studied in uveitis and has received regulatory approval for this condition. It works by blocking a protein called tumor necrosis factor-alpha (TNF-alpha), which plays a key role in inflammation. Clinical trials called VISUAL I and VISUAL II evaluated adalimumab in patients with noninfectious uveitis.^[11]

The VISUAL I trial studied adalimumab as a treatment for active uveitis while helping patients reduce their steroid use. Results showed that adalimumab significantly extended the time before patients experienced treatment failure—24 weeks compared to 13 weeks for those receiving placebo. Patients taking adalimumab also showed improvements in visual acuity and reduced inflammation in their eyes. However, they experienced more side effects related to the injection site and allergic reactions, though serious infections occurred at similar rates in both groups.^[11]

The VISUAL II trial focused on preventing flare-ups in patients whose uveitis was inactive but controlled with systemic steroids. Adalimumab significantly reduced the risk of disease flare-ups and vision loss when steroids were withdrawn, with a lower treatment failure rate of 39 percent compared to 55 percent in the placebo group.^[11]

Researchers are also investigating various approaches to treating macular edema, a common complication of uveitis where fluid accumulates in the macula, causing blurred or distorted vision. Multiple clinical trials are exploring different treatment strategies for this condition, including various medications and delivery methods that can reduce swelling and help restore clearer vision.^[11]

Current clinical trials are testing both new steroid implants and novel immunosuppressive agents. Some studies are evaluating whether using one or two fluocinolone acetonide implants provides better long-term control of inflammation. Others are examining dexamethasone implants as monotherapy, meaning they are used as the sole treatment rather than combined with other medications.^[11]

These trials are being conducted at medical centers in various locations, including the United States, Europe, and other regions. Patient eligibility for clinical trials depends on many factors, including the type and severity of uveitis, previous treatments tried, overall health status, and specific criteria set by each study. People interested in participating in a clinical trial should discuss the option with their eye doctor, who can help determine if any appropriate studies are available.

Most common treatment methods

• Corticosteroid medications
  • Steroid eye drops applied directly to the eye, typically used for anterior uveitis affecting the front of the eye
  • Oral steroids taken as pills to treat inflammation throughout the body, including deep inside the eye
  • Steroid injections administered into or around the eye for more direct delivery to affected tissues
  • Long-acting steroid implants placed inside the eye, such as dexamethasone and fluocinolone acetonide implants, which release medication slowly over months or years
• Immunosuppressive therapy
  • Methotrexate, an antimetabolite medication used as a first-line steroid-sparing agent
  • Mycophenolate mofetil, another antimetabolite with similar effectiveness to methotrexate but different side effect profile
  • Other immunosuppressants used when first-line agents are insufficient or not tolerated
• Biologic medications
  • Adalimumab, a TNF-alpha blocker that targets specific inflammatory proteins, approved for treating noninfectious uveitis
  • Used as additional agents following failure of or incomplete response to conventional immunosuppressants
  • Administered through injections, typically under the skin
• Supportive treatments
  • Dilating eye drops to relieve pain by relaxing eye muscles and preventing pupil complications
  • Treatment of underlying infections if uveitis is caused by bacteria, viruses, fungi, or parasites
  • Management of associated autoimmune or systemic diseases that may be contributing to eye inflammation